Skip to main content

Day: November 18, 2024

Newtek Bank, N.A. Launches Newtek Zero-Fee Business Banking™

Goal is to Attract Business Deposits with Full Transparency, Trust, and Low Cost BOCA RATON, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) — NewtekOne, Inc. (NASDAQ: NEWT) announced today that its national bank subsidiary, Newtek Bank, N.A., member FDIC, has launched Newtek Zero-Fee Business Banking™, which provides its commercial clients with true zero-fee business banking depository accounts without hidden banking fees or costs. Newtek Bank does not charge fees to its business banking clients for ACH, wires, monthly service charges, maintenance or activity, overdrafts, or insufficient funds and no minimum balance requirements, making its business banking account a true, trusting, zero-fee banking account. Barry Sloane, President, Chairman and CEO commented, “We are pleased to finally launch true zero-fee commercial business banking...

Continue reading

Plastic Waste Management Market is Estimated to Develop at a Slow 3.4% CAGR through 2031 | SkyQuest Technology

Westford, USA, Nov. 18, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Plastic Waste Management market will attain a value of USD 48.68 billion by 2031, with a CAGR of 3.4% over the forecast period (2024-2031). Rising emphasis on sustainability and growing environmental issyes caused by plastic waste are primarily driving the demand for plastic waste management around the world. Increasing investments in development of novel plastic waste management technologies and imposition of strict waste management regulations are also expected to drive plastic waste management market growth in the future.   Download a detailed overview: https://www.skyquestt.com/sample-request/plastic-waste-management-market Browse in-depth TOC on “Plastic Waste Management Market”Pages – 197 Tables – 95 Figures – 76Plastic...

Continue reading

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Actively Exploring Partnership for Alzheimer’s DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced financial results for the third quarter ended September 30, 2024 and provided a corporate update on its key program for Alzheimer’s disease. Treatment with pepinemab believed to slow cognitive decline due to Alzheimer’s disease: Vaccinex reported final data from its SIGNAL-AD clinical trial at the Alzheimer’s Association International Conference in Philadelphia on July 31, 2024 and at the Clinical Trials on Alzheimer’s Disease Conference in Madrid, Spain on October...

Continue reading

Treasure Global Inc. Reports First Quarter Fiscal Year 2025 Financial Results

NEW YORK and KUALA LUMPUR, Malaysia, Nov. 18, 2024 (GLOBE NEWSWIRE) — Treasure Global Inc. (NASDAQ: TGL) (“Treasure Global” or the “Company”), a leading e-commerce platform operator, had on November 14, 2024 announced its financial results for the first quarter ended September 30, 2024. Key Financial HighlightsRevenue for the first quarter was $207,371, compared to $13.46 million for the prior year’s quarter, reflecting the Company’s ongoing pivot toward high-margin business models and deliberate scaling down of low-margin operations. This strategic pivot is expected to benefit long-term revenue quality and stability. Gross profit improved by 6% to $172,172, with the gross profit margin soaring to 83.0% compared to 1.2% in the prior year’s quarter, underscoring the Company’s strategic focus on operational efficiency and high-value...

Continue reading

ParaZero Received Regulatory Approval in Europe for its Drone Safety System

ParaZero’s SafeAir M-300/ M-350 Pro parachute systems comply with key safety requirements, enabling drone operators to enhance their operational scope Tel Aviv, Israel, Nov. 18, 2024 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “Company” or “ParaZero”), an aerospace company focused on safety systems for defense and commercial drones and urban air mobility aircraft, announces that it has received the Design Verification Report (DVR) approval from the European Union Aviation Safety Agency (EASA) for its SafeAir M-300 Pro and SafeAir M-350 Pro parachute safety kits. This approval adds to ParaZero’s portfolio of previously granted approvals from the Federal Aviation Administration (FAA), alongside additional territories. The EASA DVR confirms that ParaZero’s SafeAir M-300/ M-350 Pro parachute...

Continue reading

Pineapple Energy Announces Corporate Name Change to SUNation Energy, Inc., and New Ticker Symbol

New Ticker Symbol “SUNE” Effective November 19TH, 2024 Reincorporation to Delaware Effective November 14TH, 2024 RONKONKOMA, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) — Pineapple Energy Inc. (Nasdaq: PEGY) (Pineapple Energy) (“Pineapple” or the “Company”), a leading provider of sustainable solar energy and backup power to households, businesses, municipalities, and for servicing existing systems, today announced that it has begun the effectuation of the change to its corporate name to SUNation Energy, Inc. (“SUNation”) by filing its Certificate of Incorporation with the Secretary of State of Delaware under our new name, and that the Company will begin trading on Nasdaq under the trading symbol “SUNE” on November 19th, 2024.  In connection with the corporate name change, Company branding, including the corporate website, will be updated...

Continue reading

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

– IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to placebo – – Top-line results from the Bateman Horne Center’s Long-COVID study provide key insights into final design of Dogwood’s planned Phase 2 study, projected to enroll approximately 200 participants – ATLANTA, Nov. 18, 2024 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company advancing new medicines to treat pain and fatigue-related disorders, today announced top line data from the recently completed BHC IMC-2 Long-COVID study. The study was conducted via an investigator-initiated, investigational research grant provided to the Bateman Horne Center (“BHC”)....

Continue reading

AITX’s RAD to Announce Potentially Revolutionary AI-Based Security Innovation

Game-Changing Technology to Redefine a Key Security Industry Function Detroit, Michigan, Nov. 18, 2024 (GLOBE NEWSWIRE) — Artificial Intelligence Technology Solutions, Inc. (the “Company”) (OTCPK:AITX), a global leader in AI-driven security and productivity solutions for enterprise clients, along with its subsidiary Robotic Assistance Devices (RAD), will unveil a groundbreaking technological advancement at 8:00 am ET on Wednesday, November 20, 2024. The new innovation, dubbed ‘SARATM’, promises transformative improvements in cost-efficiency and quality for a critical security industry function. RAD will provide at least one video demonstration as well as pricing information on SARA, during the announcement, showcasing the capabilities of this revolutionary AI-driven solution. Designed to meet growing demands in the security industry,...

Continue reading

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions The Company is currently developing SPC-15 as an intranasal treatment for PTSD SARASOTA, FL, Nov. 18, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced promising results from a preclinical study on SPC-15. This new formulation, which targets both the serotonin 5-HT4 receptor (5-HT4R) and the NMDA receptor (NMDAR), has shown potential as a treatment for major depressive disorder (MDD), and other severe stress-related conditions. The study highlights the...

Continue reading

American Rare Earths Engages BMO Capital Markets as Financial Adviser

Strategic Engagement to Accelerate Development of the Halleck Creek Project DENVER, Nov. 18, 2024 (GLOBE NEWSWIRE) — American Rare Earths Limited (ASX: ARR | OTCQX: ARRNF | ADR: AMRRY) (“ARR” or “the Company”) is excited to announce the engagement of BMO Capital Markets Limited (“BMO”), a globally recognized leader in metals and mining financial advisory, as its financial adviser. This engagement represents a major step forward in ARR’s vision to establish the Halleck Creek Project in Wyoming as a cornerstone of the U.S. critical minerals supply chain. Working closely with ARR and its U.S.-based subsidiary, Wyoming Rare USA Inc. (“WRI”), BMO will spearhead efforts to explore strategic investments, joint ventures, mergers and acquisitions, and/or offtake agreements that support the accelerated development...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.